Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 18/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 16/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276925 | 0.88 | HRH1 (0.69) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL6272204 | 0.87 | HRH1 (0.54) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL6268916 | 0.86 | HRH1 (0.65) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL6414784 | 0.85 | HRH1 (0.55) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL6416289 | 0.82 | HRH1 (0.78) | HRH1CYP2D6KCNH2CHRM1CHRM2 | |
| SCHEMBL6278858 | 0.79 | HRH1 (0.53) | HRH1CYP2D6KCNH2CHRM1CHRM2 | |
| SCHEMBL6414072 | 0.79 | CHRM2 (0.53) | HRH1CYP2D6KCNH2CHRM1CHRM2 | |
| SCHEMBL6269301 | 0.78 | HRH1 (0.69) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL6269092 | 0.78 | HRH1 (0.69) | HRH1CYP2D6KCNH2CHRM1CYP3A4 | |
| SCHEMBL6270598 | 0.77 | HRH1 (0.53) | HRH1CYP2D6KCNH2CHRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005097093-A1 | SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | CNR1, CNR2, MTNR1B | HRH1 104/4885CYP2D6 74/4885KCNH2 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.